Thank you for your input into this board. I would have liked to have seen a breakout of the efficacy in various subsets of the trial population. Is this vaccine as efficacious for those with high exposure rates such as hospital professionals and a breakout of efficacy for high risk populations such as 70+. Maybe FDA have published but I missed it. Skepticism of FDA pronouncements after Remdesivir and other missteps is rampant.